Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 15, 2005 - Issue 9
Submit an article Journal homepage
17
Views
1
CrossRef citations to date
0
Altmetric
Review

Immunomodulants in HIV infection

Alessandra Bandera Institute of Infectious Disease and Tropical Medicine, University of Milan, ‘Luigi Sacco' Hospital, University of Milan, Via G.B. Grassi, 74 – 20157 Milan – Italy. [email protected]
,
Giulia Marchetti Institute of Infectious Disease and Tropical Medicine, University of Milan, ‘Luigi Sacco' Hospital, University of Milan, Via G.B. Grassi, 74 – 20157 Milan – Italy. [email protected]
&
Andrea Gori Institute of Infectious Disease and Tropical Medicine, University of Milan, ‘Luigi Sacco' Hospital, University of Milan, Via G.B. Grassi, 74 – 20157 Milan – Italy. [email protected]
Pages 1115-1131 | Published online: 02 Dec 2005

Bibliography

  • PALELLA FJ JR, DELANEY KM, MOORMAN AC et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl. J. Med. (1998) 338:853–860.
  • IPPOLITO G, GALATI V, SERRAINO D, GIRARDI E: The changing picture of the HIV/AIDS epidemic. Ann. IVY Acad. Sci. (2001) 946:1–12.
  • LYLES RH, MUNOZ A, YAMASHITA T et al.: Natural history of human immunodeficency virus Type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J. Infect. Dis. (2000) 181:872–880.
  • CHUN TW, ENGEL D, BERREY MM et al.: Early establishment of a pool of latently infected, resting CD T cells during primary HIV infection. Proc. Natl. Acad. Sci. USA (1998) 95:8869–8873.
  • FINZI D, BLANKSON J, SILICIANO JD et al.: Latent infection of CD4* T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. (1999) 5:512–517.
  • BORROW P, LEWICKY H, HAHN BH et al.: Virus-specific CD8* cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus Type 1 infection. J. Virol (1994) 68:6103–6110.
  • •First evidence of control of primary viraemia coincident with expansion of HIV-specific cytotoxic cells
  • ROSENBERG E, BILLINGSLEY J, CALIENDO A et al.: Vigorous HIV-1-specific CD4* T cell responses associated with control of viremia. Science (1997) 278:1447–50.
  • ASCHER MS, SHEPPARD HW: AIDS as immune system activation: a model for pathogenesis. Clin. Exp. Immunol (1988) 73:165–167.
  • LENG Q, BORKOW G, WEISMAN Z et al.: Immune activation correlates better than HIV plasma viral load with CD4 T-cell decline during HIV infection. J. Acquired Immune Defic. Syndr. (2001) 27:389–97.
  • GIORGI JV, HULIN LE, MCKEATING JA et al.: Shorter survival in advanced human immunodeficiency virus Type 1 infection is more closely associated with T lymphocyte activation than with Plasma virus burden or virus chemokine coreceptor usage. J. Infect. Dis. (1999) 179:859–870.
  • O'CONNOR DH, ALLEN TM, VOGELTU et al.: Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat. Med. (2002) 8:493–499.
  • BETTS MR, AMBROZAK DR, DOUEK DC et al.: Analysis of total human immunodeficiency virus (HIV)-specific CD4* and CD8* T-cell responses: relationship to viral load in untreated HIV infection. J. WroL (2001) 75:11983–11991.
  • CHAMPAGNE P, OGG GS, KING AS et al.: Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature (2001) 410:106–111.
  • APPAY V DUNBAR PR, CALLAN M et al.: Memory CD8* T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. (2002) 8:379–385.
  • BLANCOU P, CHENCINER N, CUMONT MC, WAIN-HOBSON S, HURTREL B, CHEYNIER R: The infiltration kinetics of simian immunodeficiency virus-specific T cells drawn to sites of high antigenic stimulation determines local in vivo viral escape. Proc. NatL Acad. Sci. USA (2001) 98:13237–12342.
  • DOUEK DC, BRENCHLEY JM, BETTS MR et al.: HIV preferentially infects HIV-specific CD4* T cells. Nature (2002) 417:95–8.
  • PITCHER CJ, QUITTNER C, PETERSON DM et al.: HIV-1-specific CD4* T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat. Med. (1999) 5:518–525.
  • LEIBOWITZ MR, MITSUYASU RT: Immune reconstitution strategies in HIV. Curr. Infect. Dis. Rep. (2001) 3:302–308.
  • PIKETTY C, CASTIEL P, BELEC L et ell.:Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS (1998) 12:745–750.
  • RENAUD M, KATLAMA C, MALLET A et al.: Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimens. AIDS (1999) 13:669–676.
  • CONNICK E, LEDERMAN M, KOTZIN B et al.: Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J. Infect. Dis. (2000) 181:358–363.
  • NOTERMANS D, PAKKER N, HAMANN D et al. : Immune reconstitution after 2 years of successfitl potent antiretroviral therapy in previously untreated human immunodeficiency type-1 infected adults. J. Infra. Dis. (1999) 180:1050–1056.
  • WU H, KURITZKES D, MCCLERNON D et al.: Characterization of viral dynamics in human immunodeficiency virus Type 1-infected patients treated with combination antiretroviral therapy: relationship to host factors, cellular restoration, and virologic end points. J. Infect. Dis. (1999) 179:799–807.
  • DOUEK DC. Disrupting T-cell homeostasis: how HIV-1 infection causes disease. AIDS Rev (2003) 5:172–177.
  • ••A thorough review on HIV pathogenesis.
  • GROSSMAN Z, MEIER-SCHELLERSHEIM M, SOUSA AE, VICTORINO RM, PAUL WE: CD4* T-cell depletion in HIV infection: are we closer to understanding the cause? Nat. Med. (2002) 8:319–323.
  • ••An interesting revision of mechanismscausing HIV-related CD4* immunodeficit.
  • BAGBY G, HEINRICH M: Growth factors, cytokines, and the control of hematopoiesis. In: Haematology Basic Principles and Practice. Hoffman R, benz EJ, Shattil SJ (3rd Ed.) et al., Chruchill Livingstone, Philadelphia (2000):154–202.
  • LOSSO MH, BELLOSO WH, EMERY S et al.: A randomised, controlled, Phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4* cell counts 350/mm3. J. Infect. Dis. (2000) 181:1614–1621.
  • DAVEY RT JR, CHAITT DG, ALBERT MJ et al.: A randomised trial of high-versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus Type 1 infection. J. Infect. Dis. (1999) 179:849–858.
  • HENGGE UR, GOOS M, ESSER S et al.:Randomized, controlled, Phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. AIDS (1998) 12:F225–F234.
  • DAVEY R, MURPHY R, GRAZIANO FM et al.: Immunologic and virologic effects of subcutaneous interleukin-2 in combination with antiretroviral therapy. JAMA (2000) 284:183–189.
  • ARNO' A. RUIZ L, JUAN M et aL: Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus Type 1 in persons with 250/microL CD4 T cells and undetectable plasma virus load. J. Infect. Dis. (1999) 180:56–60.
  • DAVID D, NAIT-IGHIL L, DUPONT B et al.: Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment. J. Infect. Dis. (2001) 183:730–735.
  • MARCHETTI G, MERONI L, VARCHETTA Set al.: Low-dose prolonged intermittent Interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency-virus positive patients with advanced immune impairment. Infect. Dis. (2002) 186:606–616.
  • KATLAMA C, CARCELAIN G, DUVIVIER C et al.: Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study - ANRS 082. AIDS (2002) 16:2027–2034.
  • MARCHETTI G, MERONI L, MOLTENI C et al.: Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics. AIDS (2004) 18:211–216.
  • MARCHETTI G, MERONI L, MOLTENI C et al.: IL-7/IL-7 receptor system regulation following IL-2 immunotherapy in HIV-infected patients. Antiviral Therapy (2004) 9:447–452.
  • LANGE CG, LEDERMAN MM: Immune reconstitution with antiretroviral therapies in chronic HIV-1 infection. J. Anti microb. Chemother. (2003) 51:1–4.
  • ••A comprehensive review on immune effectsof HAART introduction.
  • LORI F, FOLI A. SEMINARI E et al.: Structured treatment interruptions to control HIV-1 infection. The Lancet (2000) 354:287–288.
  • •The first evidence of a possible role of structured treatment interruptions.
  • HENRY K, TEBAS P, CHERNG D et al:Interleukin-2 prior to stopping effective antiretroviral therapy prolongs time off treatment: initial results of a pilot study utilizing CD4* T-cell count 350 cells/mm3 as the threshold for restarting HAART. 11th Conference on removiruses and Opportunist Infections, San Francisco, USA (2004):248.
  • ROSENBERG E, POON SH: Immune control of HIV-1 after early treatment of acute infection. Nature (2000) 407:523–526.
  • •Paper that support the rationale for the treatment of acute HIV infection.
  • HECHT F, KAHN J, MARTINEZ-MARINO B et al: Interleukin-2 (IL-2) added to HAART in primary HIV infection enhances anti-HIV immune responses. 9th Conference on Removiruses and Opportunistic Infections, Seattle, USA (2002):249.
  • HECTH F, HARE C, MCGRATH M et al.: Interleukin-2 in conjunction with HAART in early HIV infection increases naïve and memory CD4 cells and lowers activation markers. 10th Conference on Removiruses and Opportunistic Infections, Boston, USA (2003):290.
  • LEVY Y, DURIER C, KRZYSIEK R et al:Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS (2003) 17:343–351.
  • VALDEZ H, MITSUYASU R, LANDAY Aet al.: Interleukin-2 induces increases in CD4* lymphocyte numbers but does not enhance responses to immunization: results of A5046s. J. Infect. Dis. (2003) 187:320–325.
  • SULLIVAN A, HARDY G, NELSON M et al.: Interleukin-2 associated viral breakthroughs induce HIV-1-specific CD4 T cell responses in patients on fully suppressive highly active antiretroviral therapy. AIDS (2003) 17:628–629.
  • SERETI I, ANTHONY KB, MARTINEZ-WILSON H et al: IL-2-induced CD4* T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood (2004) 104:775–780.
  • SALLUSTO F, LENIG D, FORSTER R et al.: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (1999) 401:708–712.
  • MARKERT ML, HICKS CB, BARTLETT JA et al.: Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection. AIDS Res. Hum. Removiruses (2000) 16:403–413.
  • GOLLOB JA, MIER JW, VEENSTRA K et al.: Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-y induction is associated with clinical response. Clin. Cancer Res. (2000) 6:1678–1692.
  • CLERICI M, LUCEY DR, BERZOFSKY JA et al: Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science (1993) 262: 1721-1724.
  • JACOBSON MA, HARDY D, CONNICK E, WATSON J, DEBRUIN M: Phase I trial of a singe dose of recombinant human interleukin-12 in human immunodeficiency virus-infected patients with 100-500 CD4 cells/microL. J. Infect. Dis. (2000) 182:1070–1076.
  • TRICHIERI G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol (2003) 3:133–146.
  • SHA BE, ONORATO M, BARTLETT JA et al.: Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12. AIDS (2004) 18:1203–1216.
  • TAN JT, DUDL E, LEROY E et al: IL-7 is critical for homeostatic proliferation and survival of naïve T cells. Proc. Natl. Acad. Sci.USA (2001) 98:8732–8737.
  • SCHLUNS KS, KIEPER WC, JAMESON SC, LEFRANCOIS L. Interleukin-7 mediates the homeostasis of naïve and memory CD8T cells in vivo. Nat. Immunol (2000) 1:426–432.
  • FRY TJ, MACKALL CL: Interleukin-7: master regulator of peripheral T-cell homeostasis? Trends Immunol (2001) 22:564–571.
  • •A comprehensive review of IL-7 functions.
  • NAPOLITANO LA, GRANT RM, DEEKS S et al: Increased production of IL-7 accompanies HIV-1 mediated T-cell depletion: implications for T-cell homeostasis. Nat. Med. (2001) 7:73–79.
  • •Paper that analyse the production of IL-7 in HIV infection.
  • NAPOLITANO LA: Approaches to immune reconstitution in HIV infection. Top. HIV Med. (2003) 11:160–163.
  • CHENE L, NUGEYRE MT, GUILLEMARD N, MOULIAN N, BARRE-SINOUSSI F, ISRAEL N: Thymocyte-thymic epithelial cell interaction leads to high-level replication of human immunodeficiency virus exclusively in mature CD4*CD8-CD3* thymocytes: a critical role for tumor necrosis factor and interleukin-7. j ViroL (1999) 73:7533–7542.
  • SCHMITT N, CHENE L, BOUTOLLEAU D et al: Positive regulation of CXCR4 expression and signalling by interleukin-7 in CD4* mature thymocytes correlates with their capacity to favor human immunodeficiency X4 virus replication. J. Virol (2003) 77:5784–5793.
  • CARINI C, MCLANE MF, MAYER KH, ESSEX M: Dysregulation of interleukin-7 receptor may generate loss of cytotoxic T cell response in human immunodeficiency virus Type 1 infection. Eur. J. Immunol. (1994) 24:2927–2934.
  • MACPHERSON PA, FEX C, SANCHEZ-DARDON J, HAWLEY-FOSS N, ANGEL JB: Interleukin-7 receptor expression on CD8* T cells is reduced in HIV infection and partially restored with effective antiretroviral therapy./ Acquir. Immune Defic. Syndr. (2001) 28:454–457.
  • NUGEYRE MT, MONCEAUX V, BEQ S et al: IL-7 stimulates T cell renewal without increasing viral replication in simian immunodeficiency viru-infected macaques. Immunol (2003) 171:4447–4453.
  • FRY T, MONIUSZKO M, CREEKMORE S et al: IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood (2003) 101:2294–2299.
  • AHMAD R, SINDHU ST, TOMA E, MORISSET R, AHMAD A: Studies on the production of IL-15 in HIV-infected/AIDS patients. J. Clin. Immunol (2003) 23:81–90.
  • MASTROIANNI CM, D'ETTORE G, FORCINA G et al: Interleukin-15 enhances neutrophil functional activity in patients with human immunodeficiency virus infection. Blood (2000) 96:1979-1984. Expert Opin. Ther Patents (2005) 15(9)1129
  • NAORA H, GOUGEON ML: Enhanced survival and potent expansion of the natural killer cell population of HIV-infected individuals by exogenous interleukin-15. Immunol. Lett. (1999) 68:359–367.
  • CHITNIS V, PAHWA R, PAHWA S: Determinants of HIV-specific CD8 T-cell responses in HIV-infected pediatric patients and enhancement of HIV-gag-specific responses with exogenous IL-15. Clin. Immunol. (2003) 107:36–45.
  • PETROVAS C, MUELLER YM, BOJCZUK P et al.: IL-15 treatment of SIV-infected non-human primates. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA (2004):249.
  • PERERA LP, GOLDMAN CK, WALDMANN TA: IL-15 induces the expression of chemokines and their receptors in T lymphocytes. J. Immunol. (1999) 162:2602–2612.
  • MACKEWICZ NL, LEVY JA, CRUIKSHANK WW, KORNFELD H, CENTER DM: Role of IL-16 in HIV replication. Nature (1996) 383:488–489.
  • •First report of interaction between IL-16 and HIV-replication.
  • ZHOU P, GOLDSTEIN, DEVAVDAS K, TEWARI D, NOTKINS AL: Human CD4* cells transfected with IL-16 cDNA are resistant to HIV-1 infection: inmhibition of m-RNA expression. Nat. Med. (1997) 3:659–664.
  • AMIEL C, DARCISSAC E, TRUONG MJ et al.: Interleukin-16 (IL-16) inhibits human immunodeficiency virus replication in cells from infected subjects, and serum IL-16 levels drop with disease progression. J. Infect. Dis. (1999) 179:83–91.
  • TRUONG MJ, DARCISSAC EC.A, HERMANN E, DEWULF J, CAPRON A. BAHR GM: Interleukin-16 (IL-16) inhibits human immunodeficiency virus Type 1 entry and replication in macrophages and in dendritic cells. J. Virol. (1999) 73:7008–7013.
  • PARADA NA, CENTER DM, KORNFELD H et al.: Synergistic activation of CD4* T cells by IL-16 and IL-2.J. Immunol. (1998) 160:2115–2120.
  • CHAPPEL S: Growth hormone in immunereconstitution. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. (1999) 20:423–431.
  • VIGANO A, SARESELLA M, TRABATTONI D et aL: Growth hormone in T-lymphocyte thymic and post-thymic development: a study in HIV-infected children/. Pediatr. (2004) 145:542–548.
  • NAPOLITANO L, LO JC, GOTWAY MB et al.: Increased thymic mass and circulating naïve CD4 T cells in HIV-1 infected adults treated with growth hormone. AIDS (2002) 16:1103–1111.
  • PIRES A. PIDO-LOPEZ J, MOYLE G, GAZZARD B, GOTCH F, IMAMI N: Enhanced T-cell maturation, differentiation and function in HIV-1-infected individuals after growth hormone. Antivir. Ther. (2004) 9:67–75.
  • LORI F, JESSEN H, FOLI A, LISZIEWICS J, MATTEO PS: Long-term suppression of HIV-1 by hydroxyurea and didanosine. JAMA (1997) 277:1437–1438.
  • LORI F, JESSEN H, LIEBERMAN J et al.: Treatment of human immunodeficiency virus infection with hydroxyurea, disianosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J. Infect. Dis. (1999) 180:1827–1832.
  • RUTCHMANN OT, VERNAZZA PL, BYCHER HC et al.: Long-term hydroxyurea in combination with disianosine and stavudine for the treatment of HIV-infection. AIDS (2000) 14:2145–2151.
  • GARCIA F, PLANA M, ARNEDO M et al.: A cytostatic drug improves control of HIV-1 replication durino structured treatment interruptions: a randomised study. AIDS (2003) 17:43–51.
  • LU W, SALERNO-GONCALVES R, YUAN J, SYLVIE D, HAN DS, ANDRIEU JM: Glucocorticoids rescue CD4* T lymphocytes from activation-induced apoptosis triggered by HIV-1: implications for pathogenesis and therapy. AIDS (1995) 9:35–42.
  • ANDRIEU JM, LU W, LEVY R: Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus Type 1-seropositive patients treated with prednisolone for 1 year. J. Infect. Dis. (1995) 171:523–30.
  • WALLIS RS, KALAYJIAN R, JACOBSON JM et al.: A study of immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700.1 Acquir. Immune De*. Syndr. (2003) 32:281–286.
  • FRANKE EK, YUAN HE, LUBAN J: Specific incorporation of cyclophillin A into HIV-1 virions. Nature (1994) 372:359–362.
  • •Paper that first provide rationale for the use of cyclosporin in HIV infection.
  • LEVY R, JAIS JP, TOURANI JM, EVEN P,ANDRIEU JM: Long-term follow-up of HIV positive asymptomatic patients having received cyclosporin A. Adv. Exp. Med. Biol. (1995) 374:229–234.
  • MARTIN LN, MURPHEY-CORB M, MACK P et al.: Cyclosporin A modulation of early virologic and immunologic events during primary simian immunodeficiency virus infection in rhesus monkeys. J. Infect. Dis. (1997) 176:374–383.
  • RIZZARDI GP, HARARI A, CAPILUPPI B et al.: Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. Clin. Invest. (2002) 109:681–688.
  • CHAPUIS AG, RIZZARDI GP, D'AGOSTINO C et al.: Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat. Med. (2000) 6:762–768.
  • •Paper that report mechanism of HIV suppression exerted by mycophenolic acid.
  • GARCIA F, PLANA M, ARNEDO M et al.: Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load durino and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection. J. Acquir. Immune De*. Syndr. (2004) 36:823–830.
  • RIZZARDI GP, GUARALDI G, LAZZARIN A, PANTALEO G, TAMBUSSI G: Long-term control of HIV-1 RNA replication following a unique supervized treatment interruption and mycophenolate mofetil therapy in patients treated with HAART since primary HIV-1 infection. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA (2004):210.
  • MAKONKAWKEYOON S, LIMSON-POBRE RN, MOREIRA AL, SCHAUF V, KAPLAN G: Thalidomide inhibits the replication of human immunodeficiency virus Type 1. Proc. NatL Acad. Sci. USA (1993) 90:5974–5978.
  • WOLKENSTEIN P, LATARJET J, ROUJEAU JC et al.: Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet (1998) 352:1586-1589. 1130 Expert Opin. Ther Patents (2005) 15(9)
  • JACOBSON JM, SPRITZLER J, FOX L et al.: Thalidomide for the treatment of espphageal aphtous ulcers in patients with human immunodeficiency infection. J. Infect. Dis. (1999) 180:61–67.
  • GORI A, ROSSI MC, TRABATTONI D et al.: Tumor necrosis factor-a increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection. J. Infect. Dis. (2000) 182:639.
  • HASLETT PA, HANEKOM WA, MULLER G, KAPLAN G: Thalidomide and a thalidomide analogue drug costimulate virus-specific CM* T cells in vitro. J. Infect. Dis (2003) 187:946–954.
  • •Paper that supports new evidences for the role of thalidomide in viral chronic infection.
  • RHODES J, CHEN H, HALL SR, BEESLEY JE, JENKINS DC, COLLINS P, ZHENG B : Therapeutic potentiation of the immune system by costimulatory Schiff-base-forming drugs. Nature (1995) 377:711–75.
  • CLERICI M, COGLIATI M, RIZZARDINI G et al.: In vitro immunomodulatory properties of tucaresol in HIV infection. Clin. Immunol . (2000) 97:211–220.
  • GORI A, TRABATTONI D, BANDERA A et al.: Immunomodulation induced by tucaresol in HIV infection: results of a 16 week pilot Phase I/II trial. Antiviral Therapy (2004) 9:603–614.
  • CHARO J, LINDENCRONA JA, CARLSON LM, HINKULA J, KIESSLING R: Protective efficacy of a DNA influenza virus vaccine is markedly increased by the coadministration of a Schiff base-forming drug. J. Virol (2004) 78:11321–11326.
  • BAHR GM, DARCISSAC E, BEVEC D, DUKOR P, CHEDID L: Immunopharmacological activities and clinical development of muramyl peptides with particular emphasis on murabutide. Int. J. Immunopharmacology (1995) 17:117–131.
  • DARCISSAC EC, TRUONG MJ, DEWULF J, MOUTON Y, CAPRON A, BAHR GM: The synthetic immunomodulator murabutide controls human immunodeficiency virus Type 1 replication at multiple levels in macrophages and dendritic cells. J. Virol (2000) 74:7794–7802.
  • BAHR GM, DARCISSAC EC, CASTERAN N et al.: Selective regulation of human immunodeficiency virus-infected CD4(+) lymphocytes by a synthetic immunomodulator leads to potent virus suppression in vitro and in hu-PBL-SCID mice. J. Virol. (2001) 75:6941–6952.
  • GOASDUFF T, DARCISSAC EC, VIDALV, CAPRON A, BAHR GM: The transcriptional response of human macrophages to murabutide reflects a spectrum of biological effects for the synthetic immunomodulator. Clin. Exp. Immunol (2002) 128:474–482.
  • BAHR G, COCUDE C, BILLAUT-MULOT 0, TRUONG MJ, CAPRON C: The cytokine inducer murabutide inhibits expression of a novel cellular RNA helicase necessary for HIV replication. J. Leuk. Biol. (2001) Suppl. 64.
  • AMIEL C, DE LA TRIBONNIERE X, VIDAL V DARCISSAC E, MOUTON Y, BAHR GM: Clinical tolerance and immunologic effects after single or repeated administrations of the synthetic immunomodulator murabutide in HIV-1 infected patients. J. Acquir. Immune Defic. Syndr. (2002) 30:294–305.
  • DE LA TRIBONNIERE X, MOUTON Y, VIDAL V et cll.: A Phase I study of a six-week cycle of immunotherapy with murabutide in HIV-1 patients naive to antiretrovirals. Med Sci. Monit. (2003) 9:PI43–P150.
  • BAHR GM, DE LA TRIBONNIERE X, DARCISSAC E et al.: Clinical and immunological effects of a 6 week immunotherapy cycle with murabutide in HIV-1 patients with unsuccessful long-term antiretroviral treatment. J. Antimicrob. Chemother. (2003) 51:1377-1388. Patents

Websites

  • http://www.iatec.com/index2.html SILCAAT study design.
  • http://www.espritstudy.org ESPRIT IL-2 trial. Affiliation

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.